|
CA2790866C
(en)
*
|
2010-02-23 |
2019-02-12 |
Sanofi |
Anti-alpha2 integrin antibodies and their uses
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
WO2012096975A2
(en)
*
|
2011-01-13 |
2012-07-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy
|
|
BR112013023918A2
(pt)
|
2011-03-25 |
2016-12-13 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
|
|
WO2013008171A1
(en)
|
2011-07-11 |
2013-01-17 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to ox40 and their uses
|
|
HRP20220224T1
(hr)
|
2011-08-16 |
2022-04-29 |
Morphosys Ag |
Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
|
|
KR20140064873A
(ko)
|
2011-08-16 |
2014-05-28 |
모르포시스 아게 |
항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
|
|
AU2013322710A1
(en)
|
2012-09-25 |
2015-04-16 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
MX338711B
(es)
|
2012-10-12 |
2016-04-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
EP2906296B1
(en)
|
2012-10-12 |
2018-03-21 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
HRP20182129T1
(hr)
*
|
2012-10-12 |
2019-02-08 |
Adc Therapeutics Sa |
Konjugati protutijelo - pirolobenzodiazepin
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
WO2014106602A1
(en)
|
2013-01-02 |
2014-07-10 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to tl1a and their uses
|
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたｔリンパ球
|
|
UY35468A
(es)
*
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
EP3013856A2
(en)
*
|
2013-06-27 |
2016-05-04 |
AbbVie Biotherapeutics Inc. |
Fc variants with improved complement activation
|
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN105873952A
(zh)
*
|
2013-10-31 |
2016-08-17 |
弗莱德哈钦森癌症研究中心 |
经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
|
|
JP2016538275A
(ja)
|
2013-11-04 |
2016-12-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
WO2015179801A1
(en)
|
2014-05-23 |
2015-11-26 |
University Of Florida Research Foundation, Inc. |
Car based immunotherapy
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
TWI751102B
(zh)
*
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2016061368A1
(en)
*
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
MA41480A
(fr)
|
2014-10-17 |
2017-12-19 |
Glenmark Pharmaceuticals Sa |
Anticorps qui se lient au ccr6 et leurs utilisations
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
ES2819553T3
(es)
|
2014-12-03 |
2021-04-16 |
Juno Therapeutics Inc |
Métodos y composiciones para terapia celular adoptiva
|
|
US12428483B2
(en)
*
|
2014-12-22 |
2025-09-30 |
Systimmune, Inc. |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
WO2016134284A1
(en)
*
|
2015-02-19 |
2016-08-25 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
|
GB201503742D0
(en)
*
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
WO2016168769A1
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Chimeric receptor t cell switches for her2
|
|
EP3288569A4
(en)
*
|
2015-04-29 |
2018-12-19 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
LT3302550T
(lt)
|
2015-05-26 |
2019-11-11 |
Morphosys Ag |
Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
|
|
EP3149046B1
(en)
*
|
2015-07-24 |
2020-02-26 |
Innovative Cellular Therapeutics Co., Ltd. |
Humanized anti-cd19 antibody and use thereof
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
RU2767063C2
(ru)
|
2015-08-21 |
2022-03-16 |
МорфоСис АГ |
Комбинации и их использование
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055314A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
AU2016330807B2
(en)
|
2015-10-02 |
2023-08-10 |
F. Hoffmann-La Roche Ag |
Anti-human CD19 antibodies with high affinity
|
|
EP4212166A1
(en)
*
|
2015-12-03 |
2023-07-19 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against cell therapies
|
|
EP4212547A1
(en)
|
2015-12-03 |
2023-07-19 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
FI3916392T3
(fi)
|
2016-05-30 |
2024-06-03 |
Incyte Corp |
Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
|
|
WO2018002031A1
(en)
|
2016-06-27 |
2018-01-04 |
Morphosys Ag |
Anti-cd19 antibody formulations
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
EP3529268B1
(en)
*
|
2016-10-19 |
2025-02-26 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
JP7100028B2
(ja)
|
2016-10-20 |
2022-07-12 |
セルジーン コーポレイション |
セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
|
|
US12358983B2
(en)
|
2016-10-28 |
2025-07-15 |
Incyte Corporation |
Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
CN110248677B
(zh)
*
|
2017-01-05 |
2023-05-16 |
上海煦顼技术有限公司 |
人源化抗cd19抗体及其与嵌合抗原受体的用途
|
|
RS61795B1
(sr)
|
2017-02-08 |
2021-06-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin antitela
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN106967171B
(zh)
*
|
2017-02-23 |
2021-04-27 |
郑州大学 |
一种全人源重组CD40L单抗Fab片段及其制备方法
|
|
CN110582505B
(zh)
|
2017-04-18 |
2021-04-02 |
免疫医疗有限公司 |
吡咯并苯并二氮杂*缀合物
|
|
EP3612210A4
(en)
|
2017-04-19 |
2021-01-27 |
Board Of Regents, The University Of Texas System |
MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
|
|
AU2018257894A1
(en)
*
|
2017-04-24 |
2019-10-31 |
Kite Pharma, Inc. |
Humanized antigen-binding domains against CD19 and methods of use
|
|
AU2018265261B2
(en)
*
|
2017-05-10 |
2025-05-22 |
Inovio Pharmaceuticals, Inc. |
Optimized nucleic acid antibody constructs
|
|
LT3630177T
(lt)
|
2017-05-31 |
2023-10-25 |
Morphosys Ag |
Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
|
|
CA3064804A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd19 adc
|
|
EA202090020A1
(ru)
|
2017-07-10 |
2020-04-28 |
Интернэшнл - Драг - Дивелопмент - Байотек |
Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
|
|
US11447546B2
(en)
*
|
2017-07-20 |
2022-09-20 |
Nbe-Therapeutics Ag |
Human antibodies binding to ROR2
|
|
KR102270107B1
(ko)
|
2017-08-18 |
2021-06-30 |
메디뮨 리미티드 |
피롤로벤조디아제핀 컨쥬게이트
|
|
EP3684820A4
(en)
|
2017-09-21 |
2021-05-26 |
Wuxi Biologics (Cayman) Inc. |
NEW ANTI-CD19 ANTIBODIES
|
|
SG11202003879RA
(en)
|
2017-10-30 |
2020-05-28 |
Neuropore Therapies Inc |
Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
|
|
KR102136063B1
(ko)
|
2017-12-06 |
2020-07-22 |
앱클론(주) |
악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항체 수용체 및 이의 용도
|
|
EP3730519B1
(en)
*
|
2017-12-22 |
2023-09-13 |
AbClon Inc. |
Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof
|
|
CN109053899B
(zh)
|
2017-12-22 |
2021-11-16 |
湖南远泰生物技术有限公司 |
一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
|
|
CN108047332B
(zh)
*
|
2018-01-15 |
2021-08-24 |
阿思科力(苏州)生物科技有限公司 |
以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
US12473336B2
(en)
|
2018-02-21 |
2025-11-18 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses thereof
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
CN109293774B
(zh)
*
|
2018-10-16 |
2021-05-28 |
南京医科大学 |
特异性结合cd19的全人源化抗体及应用
|
|
EP3883635A1
(en)
|
2018-11-19 |
2021-09-29 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
AU2019397033B2
(en)
|
2018-12-12 |
2023-06-29 |
Kite Pharma, Inc. |
Chimeric antigen receptors and CAR-T cells and methods of use
|
|
JP7090780B2
(ja)
*
|
2018-12-21 |
2022-06-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に結合する抗体
|
|
CR20210330A
(es)
|
2018-12-21 |
2021-07-20 |
Hoffmann La Roche |
ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
CN113631560B
(zh)
|
2019-03-15 |
2025-02-18 |
麦迪穆有限责任公司 |
氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
|
|
CA3136251A1
(en)
*
|
2019-04-08 |
2020-10-15 |
Memorial Sloan Kettering Cancer Center |
Cd19 antibodies and methods of using the same
|
|
MX2021013359A
(es)
*
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
AU2020267823A1
(en)
|
2019-05-03 |
2021-11-11 |
Incyte Corporation |
Anti-CD19 therapy in patients having a limited number of NK cells
|
|
WO2020261219A1
(en)
*
|
2019-06-27 |
2020-12-30 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
MY208387A
(en)
|
2019-07-09 |
2025-05-05 |
Beijing Solobio Genetechnology Co Ltd |
Antibodies specifically recognizing pseudomonas pcrv and uses thereof
|
|
CN110396129B
(zh)
*
|
2019-07-10 |
2020-11-24 |
武汉思安医疗技术有限公司 |
人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
CN115151565A
(zh)
|
2019-10-31 |
2022-10-04 |
莫佛塞斯公司 |
包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
|
|
TW202525340A
(zh)
|
2019-10-31 |
2025-07-01 |
美商英塞特公司 |
用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
CN115666704B
(zh)
|
2019-12-13 |
2025-09-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
WO2021161197A1
(en)
*
|
2020-02-11 |
2021-08-19 |
Crispr Therapeutics Ag |
Anti-idiotype antibodies targeting anti-cd19 chimeric antigen receptor
|
|
US20210340524A1
(en)
*
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
|
WO2021259902A1
(en)
|
2020-06-22 |
2021-12-30 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
|
|
WO2022076573A1
(en)
|
2020-10-06 |
2022-04-14 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
CN116848147A
(zh)
*
|
2020-11-20 |
2023-10-03 |
先声再明医药有限公司 |
Cd19人源化抗体及其应用
|
|
WO2022117799A2
(en)
|
2020-12-04 |
2022-06-09 |
Morphosys Ag |
Anti-cd19 combination therapy
|
|
US20240425563A1
(en)
*
|
2021-01-13 |
2024-12-26 |
Washington University |
MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
|
|
CN112679612B
(zh)
*
|
2021-01-29 |
2022-07-01 |
武汉华美生物工程有限公司 |
抗cd19人源化抗体及其制备方法与应用
|
|
IL308296A
(en)
*
|
2021-05-07 |
2024-01-01 |
Viela Bio Inc |
Use of anti-CD19 antibody to treat myasthenia gravis
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
KR20250052388A
(ko)
|
2022-08-17 |
2025-04-18 |
인사이트 코포레이션 |
항-cd19 항체 및 ezh2 조절제를 포함하는 요법
|
|
KR20260006623A
(ko)
*
|
2023-04-28 |
2026-01-13 |
센젠 센신 바이오테크놀로지 컴퍼니 리미티드 |
변형된 전달 담체 및 이의 용도
|
|
KR20260022392A
(ko)
|
2023-06-09 |
2026-02-19 |
제이더블유 테라퓨틱스 알 & 디 (상하이) 컴퍼니, 리미티드 |
융합 단백질 및 그의 의학적 용도
|
|
US20250197501A1
(en)
*
|
2023-12-19 |
2025-06-19 |
Development Center For Biotechnology |
Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers
|